Saturday, February 25, 2023 | 10:00 am – 12:30 pm ET
- Current Approaches to Reduce Lp(a)
- Emerging Therapies for Lp(a) Reduction
- Panel Discussion: Lp(a), Therapeutic Landscape, and CV Risk
- Clinical Cases
- LIVE Question & Answer
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Despite its demonstrated contribution to atherosclerotic cardiovascular disease burden, there is a lack of standardization and harmonization of assays, universal guidelines for diagnosing and providing risk assessment, and targeted treatments to lower Lp(a). In this CE program, expert faculty review the pathophysiology and accurate measurement of Lp(a), implications of increased Lp(a) levels on cardiovascular risk, as well as current and emerging therapeutic approaches to manage patients with elevated Lp(a). These sessions, incorporate didactic presentations covering the pathophysiology of Lp(a), current and emerging therapies for Lp(a) reduction, associated risks, guidelines, clinical cases, and the patient experience, as well as including a live question-and-answer session.
The intended audience for these activities are cardiologists, endocrinologists, lipidologists, internists, family medicine physicians, pharmacists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with cardiovascular risk factors.
Upon successful completion of these activities, participants should be better able to:
- Describe the structure and pathophysiology of Lp(a).
- Review the role of Lp(a) as a risk factor in atherosclerotic cardiovascular disease.
- Outline the current approaches to treat patients with elevated Lp(a).
- Summarize the emerging therapies for the management of patients with elevated Lp(a).
- Outline the challenges and modalities involved in the measurement of Lp(a).
- Assess the significance of Lp(a) as a tool for cardiovascular risk assessment.
- Examine evidence-based strategies to identify patients who are at risk for cardiovascular events and may benefit from reduction of Lp(a).